KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
KYNTRA BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.28+0.43 (+8.87%)
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
KYNTRA BIO, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug Product Revenue [Member] | $3.95M | $6.75M | $5.85M | $7.49M | $6.27M | $5.78M | $27.67M | $26.01M | $27.59M | $41.13M | $18.75M | $24.18M | 85.6% | -36.9% |
| Other Revenue - Contract Manufacturing [Member] | $664.00K | $694.00K | $592.00K | $812.00K | $1.08M | $1.21M | $1.95M | $4.11M | $10.50M | $15.39M | $18.40M | $20.34M | 14.4% | -38.4% |
| License [Member] | – | – | – | – | – | – | $0 | $0 | $2.65M | $3.65M | $9.65M | $9.65M | – | – |
| Product [Member] | – | – | – | – | – | – | – | $149.90M | $133.08M | $107.33M | $100.95M | $100.81M | – | – |
By region
From the segment and revenue-disaggregation notes of Kyntra Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.